100 Bayer Boulevard
It all starts with a friendship between two men, plenty of natural curiosity and two kitchen stoves. Businessman Friedrich Bayer and dyer Johann Friedrich Weskott use these to conduct experiments and eventually discover how to make the dye fuchsine.
On August 1, 1863, they found the "Friedr. Bayer et. comp." company in Wuppertal-Barmen, a 19th century startup with tremendous potential.
Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time.
Our goal is to create value for our customers, stockholders and employees, while also strengthening the company’s earning power. We are committed to operating sustainably and addressing our social and ethical responsibilities. Employees with a passion for innovation enjoy excellent development opportunities at Bayer.
All this goes to make up our purpose: Science for a better life.
Passion to innovate | Power to change
688 articles with Bayer
Bayer to Present Results from Head-to-Head PK Comparison Study of Jivi® Versus Adynovate® in Late-Breaker Presentation at the Annual World Federation of Hemophilia Virtual Summit
Bayer to Present Results from Head-to-Head PK Comparison Study of Jivi ® Versus Adynovate ® in Late-Breaker Presentation at the Annual World Federation of Hemophilia Virtual Summit WHIPPANY, N.J.--( BUSINESS WIRE )-- Bayer announced today it will present new data highlighting the results from the first head-to-head study directly comparing the pharmacokinetic (PK) profiles of two extended half-life (EHL) recombinant factor VIII (FVIII) therapies, Jivi ® (
Bayer Extends Clinical Development Program for Finerenone with Phase III Study in Patients with Heart Failure and Preserved Ejection Fraction
Bayer announced today the initiation of the FINEARTS-HF study, a multicenter, randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of investigational finer
Applying Prosaro® fungicide at early flowering helps protect grain quality, yield and profitability in cereal crops
Evotec licenses novel polycystic ovary syndrome target identified by Celmatix through its Reproductive Atlas™ platform to Bayer
Bayer Launches the Second Annual Pulmonary Hypertension Accelerated Bayer (PHAB) Awards to Encourage and Recognize Innovation in Pulmonary Research
Bayer Launches the Second Annual Pulmonary Hypertension Accelerated Bayer (PHAB) Awards to Encourage and Recognize Innovation in Pulmonary Research Awards program underscores the importance of critical clinical research to deepen understanding of pulmonary disease to help improve patient outcomes WHIPPANY, N.J.--( BUSINESS WIRE )-- Bayer announced today the launch of the second annual Pulmonary Hypertension Accelerated Bayer (PHAB) Awards to support cl
6/1/2020In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.
The Efficacy of Vitrakvi® (larotrectinib) Further Demonstrated High Response Rates and Duration of Response in an Updated Analysis and New Quality of Life Data to Be Presented at ASCO
The Efficacy of Vitrakvi ® (larotrectinib) Further Demonstrated High Response Rates and Duration of Response in an Updated Analysis and New Quality of Life Data to Be Presented at ASCO Intended for U.S. Media Only 71 percent overall response rate (ORR) per investigator assessment and median duration of response of 35.2 months shown in expanded data set of 116 adult patients with TRK fusion cancer 1 Among patients with brain metastases, ORR was
Numerous biopharmaceutical companies and researchers are presenting research and clinical trial results, and many have been announcing their plans for several weeks.
Bayer Fund Awards Millions of Dollars in Grants to Help Thousands of Americans, During the COVID-19 Pandemic
Bayer Fund, a philanthropic arm of life sciences company Bayer, today awarded more than $4 million in grants to 250 charities and non-profit organizations throughout the United States.
5/18/2020Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look.
Bayer and ArcherDX Announce Global Collaboration to Develop Next-Generation Sequencing (NGS)-based Companion Diagnostic (CDx) for VITRAKVI® (larotrectinib)
Bayer and ArcherDX Announce Global Collaboration to Develop Next-Generation Sequencing (NGS)-based Companion Diagnostic (CDx) for VITRAKVI ® (larotrectinib) Collaboration will focus on development of a companion diagnostic (CDx) for Vitrakvi ® , the first-in-class tyrosine kinase (TRK) inhibitor approved in the U.S. and Europe for adult and pediatric patients with TRK fusion cancer across all solid tumors. Vitrakvi has the largest and longest-term data set
NUBEQA® (darolutamide) Plus Androgen Deprivation Therapy Showed a Statistically Significant Improvement in Overall Survival with Proven Efficacy and Tolerability in Men with Non-Metastatic Castration-Resistant Prostate Cancer
NUBEQA reduced the risk of death by 31 percent (HR=0.69, 95% CI 0.53-0.88; p=0.003) compared to placebo in its secondary endpoint of overall survival in men with non-metastatic castration-resistant prostate cancer (nmCRPC)
Company's Generation 3 Antibody Platform Delivers High-Affinity, Drug-Like Antibody Candidates Well Designed to Facilitate the Development of High-Quality Therapeutics
Data on final analysis of overall survival (OS) from the Phase III ARAMIS trial investigating NUBEQA® (darolutamide) in men with non-metastatic castration-resistant prostate cancer (nmCRPC)
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 11, 2020.
Bayer and NeoGenomics Launch the Test4TRK™ Program to Provide Genomic Cancer Testing at No Cost for People Living with Advanced Thyroid and Colorectal Cancers
Bayer to cover testing costs for patients with RAI-refractory (RAI-R) differentiated thyroid carcinoma (DTC) and metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H) The results of a genomic cancer test can help healthcare providers determine appropriate treatment plans for people with an NTRK gene fusion NTRK gene fusions can drive tumor growth and are more common in MSI-H mCRC and RAI-R DTC cases than other subt
Bayer and OrigiMed reached a partnership to develop a next generation sequencing (NGS) based companion diagnostic-in vitro diagnostic (CDx-IVD) product in China for Larotrectinib, for NTRK gene fusion detection
The collaboration will begin with the development of a CDx-IVD for larotrectinib for the Chinese market. Larotrectinib is the world's first TRK inhibitor to be approved in patients with TRK gene fusion cancer in all solid tumors in the United States (2018) and Europe (2019)
4/28/2020Many of the companies reported increased sales for the quarter as customers increased stockpiles and inventory in preparation for the pandemic, while other forms of sales and clinical trials were negatively impacted.
Bayer to Highlight Clinical Data on Vitrakvi® (larotrectinib) and Research on Investigational AhR Inhibitor at AACR 2020 Virtual Meeting
Additional analyses from clinical trials may further aid in identifying the appropriate patients for Vitrakvi® (larotrectinib), including a presentation on patient outcomes by prior therapy and performance status Featured research includes an oral presentation in the Plenary Session on efficacy and safety outcomes in patients with NTRK gene fusions or other alterations Structure and functional characterization of investigational sma
The COVID-19 pandemic is having a devastating effect on global business and biopharma companies are not excluded.